PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE SYSTEMIC EXPOSURE OF GEFITINIB IN THE CYP2D6 ULTRARAPID METABOLIZERS AND EXTENSIVE METABOLIZERS.

被引：0
|
作者：
Chen, Y. [1 ]
Zhou, W. [1 ]
Tang, W. [1 ]
Zhou, D. [1 ]
Masson, E. [1 ]
机构：
[1] Astrazeneca, Waltham, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-021
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [31] High prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations
    Sarmiento, Alba P.
    Dorado, Pedro
    Borbon, Angelica
    de Andres, Fernando
    LLerena, Adrian
    Moya, Graciela E.
    Ferreiro, Veronica
    Tarazona-Santos, Eduardo
    Rodrigues-Soares, Fernanda
    Barrantes, Ramiro
    Jimenez-Arce, Gerardo
    Cespedes-Garro, Carolina
    Rodeiro, Idania
    Delgado, Rene
    Remirez, Diadelis
    Calzadilla, Luis R.
    Teran, Enrique
    Hernandez, Francisco
    Teran, Santiago
    Ortiz-Lopez, Rocio
    Rojas-Martinez, Augusto
    Perez-Paramo, Yadira X.
    Lopez-Lopez, Marisol
    Ortega-Vazquez, Alberto
    Monroy-Jaramillo, Nancy
    Jung-Cook, Helgi
    Fricke-Galindo, Ingrid
    Sosa-Macias, Martha
    Galaviz-Hernandez, Carlos
    Lares-Aseff, Ismael
    Lazalde-Ramos, Blanca P.
    Ramirez-Roa, Ronald
    Tinoco, Catalina Altamirano
    Grazina, Manuela
    Penas-Lledo, Eva M.
    Cobaleda, Jesus
    Farinas, Humberto
    Estevez-Carrizo, Francisco E.
    PHARMACOGENOMICS, 2020, 21 (17) : 1227 - 1236
  • [32] Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing
    P. Lindskov Krog
    O. Østerberg
    P. Gundorf Drewes
    Å. Rembratt
    A. Schultz
    W. Timmer
    European Journal of Drug Metabolism and Pharmacokinetics, 2013, 38 : 43 - 51
  • [33] Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing
    Krog, P. Lindskov
    Osterberg, O.
    Drewes, P. Gundorf
    Rembratt, A.
    Schultz, A.
    Timmer, W.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2013, 38 (01) : 43 - 51
  • [34] Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan
    Kevorkian, JP
    Michel, C
    Hofmann, U
    JacqzAigrain, E
    Kroemer, HK
    Peraldi, MN
    Eichelbaum, M
    Jaillon, P
    FunckBrentano, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (05) : 583 - 592
  • [35] Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers
    Özdemir, V
    Tyndale, RF
    Reed, K
    Herrmann, N
    Sellers, EM
    Kalow, W
    Naranjo, CA
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (05) : 472 - 475
  • [36] Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
    Aklillu, E
    Persson, I
    Bertilsson, L
    Johansson, I
    Rodrigues, F
    IngelmanSundberg, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 278 (01): : 441 - 446
  • [37] Physiologically Based Pharmacokinetic Modeling of Propranolol in Relation to <it>CYP2D6</it> Genotypes
    Lee, Choong-Min
    Jung, Eui-Hyun
    Cho, Chang-Keun
    Oh, Kyung-Yul
    Shin, Hyo-Bin
    Lim, Chang-Woo
    Byeon, Ji-Young
    Lee, Seok-Yong
    FASEB JOURNAL, 2020, 34
  • [38] Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.
    Opdam, Frans
    Dezentje, Vincent O.
    den Hartigh, Jan
    Guchelaar, Henk-jan
    Hessing, Trees
    van der Straaten, Tahar
    Vree, Robert
    Batman, Erdogan
    Maartense, Eduard
    Smorenburg, Carolien H.
    Zeillemaker, Anneke
    Brakenhoff, J. A. C.
    Los, Maartje
    Kuijer, Philomeen
    Putter, Hein
    Dieudonne, Anne-Sophie
    Maven, Patrick
    Van De Velde, Cornelis J. H.
    Nortier, J. W. R.
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups
    Ruedesheim, Simeon
    Selzer, Dominik
    Fuhr, Uwe
    Schwab, Matthias
    Lehr, Thorsten
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (04): : 494 - 511
  • [40] Low frequency of CYP2D6 poor metabolizers among schizophrenia patients
    A LLerena
    P Dorado
    E M Peñas-LLedó
    M C Cáceres
    A De la Rubia
    The Pharmacogenomics Journal, 2007, 7 : 408 - 410
12345